ホーム › 卵巣がん › バージニア › Arlington
Arlington、VAにおける卵巣がんの臨床試験
Arlingtonとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する46件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Inova Fairfax Hospital, Falls Church · 4マイル先
- Inova Schar Cancer Institute, Fairfax · 11マイル先
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
被験者募集中第1/2相
- Research Site, Fairfax · 11マイル先
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology - Virginia, Fairfax · 11マイル先
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- NEXT Virginia, Fairfax · 11マイル先
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
被験者募集中第2相
- Next Virginia /ID# 279684, Fairfax · 11マイル先
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
被験者募集中第1相
- Site 04, Fairfax · 11マイル先
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
被験者募集中第1相
- Next Virginia /ID# 278607, Fairfax · 11マイル先
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
被験者募集中第1/2相
- NEXT Virginia, Fairfax · 11マイル先
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456, Fairfax · 11マイル先
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Site 0322 - Inova Schar Cancer Institute, Fairfax · 11マイル先
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Fairfax · 11マイル先
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- NEXT Oncology Virginia, Fairfax · 11マイル先
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
被験者募集中第3相
- Virginia Cancer Specialists (VCS) ( Site 8012), Fairfax · 11マイル先
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- NEXT Oncology, Fairfax · 11マイル先
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Next Oncology Virginia, Fairfax · 11マイル先
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
被験者募集中第1相
- NEXT Oncology, Fairfax · 11マイル先
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
被験者募集中第3相
- Virginia Cancer Specialists (VCS) ( Site 8011), Fairfax · 11マイル先
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Inova Schar Cancer Institute, Falls Church · 4マイル先
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, Fairfax · 11マイル先
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Inova Fairfax Hospital, Falls Church · 4マイル先
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Clinical Trial Site, Fairfax · 11マイル先
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11マイル先
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR Virginia Cancer Specialists, Fairfax · 11マイル先
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
被験者募集中第2相
- 522, Fairfax · 11マイル先
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- USO-Virginia Cancer Specialists, PC, Fairfax · 11マイル先
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- NEXT Oncology Virginia, Fairfax · 11マイル先
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- NEXT, Fairfax · 11マイル先
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- NEXT Oncology Virginia, Fairfax · 11マイル先
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
被験者募集中第1相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology, Fairfax · 11マイル先
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Fairfax · 11マイル先
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
被験者募集中第1相
- Next Oncology, Virginia Cancer Specialists, Fairfax · 11マイル先
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
- Pittsburgh, PA30件の研究
Arlingtonにおける他の研究
- 非小細胞肺癌104件の研究
- 転移性癌53件の研究
- 大腸癌52件の研究
- がん（全種類）48件の研究
- 乳がん47件の研究
- 肺がん41件の研究
- 子宮内膜がん39件の研究
- 膵臓がん33件の研究
- 頭頸部扁平上皮癌26件の研究
- 小細胞肺がん23件の研究
- 胃癌20件の研究
- トリプルネガティブ乳がん20件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。